Intensive insulin therapy in patients with type 2 diabetes: Implications of the veterans affairs (VA CSDM) feasibility trial

American Heart Journal

Volumn 138, Issue 5 I, 1999, Pages

  Abraira, C ^a   McGuire, D K ^a  

^a HINES VA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; INSULIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; CARDIOVASCULAR RISK; CONFERENCE PAPER; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 0032693412     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70036-0     Document Type: Conference Paper

References (26)

1. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 1993;329:977-86.
2. Abraira C, Colwell JA, Nuttall F, et al. VA Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes: results of the feasibility trial. Diabetes Care 1995;18:1113-23.
3. Abraira C, Colwell J, Nuttall F, et al, for the VA CSDM Group. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Arch Intern Med 1997;157:181-8.
4. Levin S, Coburn J, Abraira C, et al, for the VA CSDM Group. Glycemic control retards progression of albuminuria in NIDDM [abstract]. Diabetes 1996;45(suppl 2):3A.
5. Kleinman JC, Donahue RP, Harris MI, et al. Mortality among diabetics in a national sample. Am J Epidemiol 1988;128:389-401.
6. Janka HU, Ziegler AG, Standl E, et al. Daily insulin dose as predictor of macrovascular disease in insulin treated non-insulin dependent diabetes. Diabetes Metab Rev 1987;13:359-64.
7. Manson JA, Colditz GA, Stampler MJ, et al. A prospective study of maturity onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991;151:1141-7.
8. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995;18:258-68.
9. Ohkkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
10. Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular mortality, and the UGDP. Am Heart J 1999;138:S346-52.
11. Meinert CL, Knatterud GL, Prout TE, et al. University Group Diabetes Program: a study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes, II: mortality results. Diabetes 1970;19(suppl 2):789-830.
12. Adler AI, Neil HAW, Manley SE, et al, for the UKPDS Study Group. Hyperglycemia and Hyperinsulinemia at Diagnosis of Diabetes and Their Association with Subsequent Cardiovascular Disease in the United Kingdom Prospective Diabetes Study (UKPDS 47). Am Heart J 1999;138:S353-9.
13. Standl E. Hyperinsulinemia and atherosclerosis. Clin Invest Med 1995;18:2612-66.
14. Arrants J. Hyperinsulinemia and cardiovascular risk. Heart Lung 1994;23:118-22.
15. Kraus W. Insulin resistance syndrome and cardiovascular disease: genetics and connections to skeletal muscle function. Am Heart J 1999;138:S413-6.
16. Sowers JR. Insulin resistance, hyperinsulinemia, dyslipidemia, hypertension, and accelerated atherosclerosis. J Clin Pharmacol 1992;32:529-35.
17. Abraira C, Maki K. Does insulin treatment increase cardiovascular risk in NIDDM? Clin Diabetes 1995;13:29-31.
18. Abraira C, Henderson W, Colwell J, et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. Diabetes Care 1998;21:574-9.
19. Siperstein MD, Browner WS. The case for moderate rather than tight glucose control in insulin-dependent diabetes mellitus. Clin Diabetes 1995;13:7-9.
20. Jokl R, Colwell JA. Arterial thrombosis and atherosclerosis in diabetes. Diabetes Rev 1997;5:316-30.
21. Missov RM, Stolk RP, der Bom JG, et al. Plasma Fibrinogen in NIDDM: the Rotterdam Study. Diabetes Care 1996;19:157-9.
22. Emanuele N, Azad N, Abraira C, et al, for the VA CSDM Group. The effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins in the VA Cooperative Study in type 2 diabetes (VA CSDM). Arch Intern Med 1998;58:2485-90.
23. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM, II: analysis of the health benefits and cost effectiveness of treating NIDDM. Diabetes Care 1997;20;735-44.
24. Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med 1997;127:788-95.
25. Ferris FL. How effective are treatments for diabetic retinopathy? JAMA 1993;269:1290-1.
26. Emanuele N, Klein R, Abraira C, et al. Evaluations of retinopathy in the VA Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Diabetes Care 1996;19:1375-81.